Multitargeted anti-angiogenic agents and NSCLC: clinical update and future directions
- PMID: 22405734
- DOI: 10.1016/j.critrevonc.2012.02.004
Multitargeted anti-angiogenic agents and NSCLC: clinical update and future directions
Abstract
Increasing understanding of the molecular abnormalities driving cell growth and proliferation has resulted in extensive research into molecularly targeted therapies. Angiogenesis is an appealing target for the treatment of non small cell lung cancer (NSCLC). Bevacizumab, a monoclonal antibody against circulating vascular endothelial growth factor (VEGF), is already approved for the treatment of NSCLC. Many other anti-angiogenic agents under development form the focus of this review. A variety of agents, including sorafenib, sunitinib, cediranib, axitinib, motesanib, linifinib and brivanib inhibit VEGF in addition to either platelet derived growth factor (PDGF), or fibroblast derived growth factor (FGF). To date, none of these agents in combination with chemotherapy have resulted in improvements in overall survival for patients with advanced NSCLC. Triple angiokinase inhibitors, which inhibit VEGF, PDGF and FGF, have potential to improve the therapeutic outcomes for patients with NSCLC. However, there is a need for identification of appropriate biomarkers to improve patient selection and identify those patients benefiting from anti-angiogenesis therapy.
Copyright © 2012 Elsevier Ireland Ltd. All rights reserved.
Similar articles
-
The emerging role of vascular endothelial growth factor receptor tyrosine kinase inhibitors.Semin Oncol. 2005 Dec;32(6 Suppl 10):S23-9. doi: 10.1053/j.seminoncol.2005.10.005. Semin Oncol. 2005. PMID: 16459176 Review.
-
Antivascular agents for non-small-cell lung cancer: current status and future directions.Expert Opin Investig Drugs. 2009 Nov;18(11):1667-86. doi: 10.1517/13543780903336050. Expert Opin Investig Drugs. 2009. PMID: 19877762 Review.
-
Targeted therapies for non-small cell lung cancer.Lung Cancer. 2010 Mar;67(3):257-74. doi: 10.1016/j.lungcan.2009.10.012. Epub 2009 Nov 14. Lung Cancer. 2010. PMID: 19914732 Review.
-
Fibroblast growth factor signaling in non-small-cell lung cancer.Clin Lung Cancer. 2012 Mar;13(2):90-5. doi: 10.1016/j.cllc.2011.08.001. Epub 2011 Sep 29. Clin Lung Cancer. 2012. PMID: 21959109 Review.
-
BIBF 1120 for the treatment of non-small cell lung cancer.Expert Opin Investig Drugs. 2010 Jun;19(6):789-94. doi: 10.1517/13543784.2010.488220. Expert Opin Investig Drugs. 2010. PMID: 20465363 Review.
Cited by
-
State-of-the-art combination treatment strategies for advanced stage non-small cell lung cancer.Front Oncol. 2022 Aug 1;12:958505. doi: 10.3389/fonc.2022.958505. eCollection 2022. Front Oncol. 2022. PMID: 35978836 Free PMC article. Review.
-
Role of the NRP-1-mediated VEGFR2-independent pathway on radiation sensitivity of non-small cell lung cancer cells.J Cancer Res Clin Oncol. 2018 Jul;144(7):1329-1337. doi: 10.1007/s00432-018-2667-8. Epub 2018 May 17. J Cancer Res Clin Oncol. 2018. PMID: 29777301
-
Anti-angiogenic therapy in advanced non-small cell lung carcinoma (NSCLC): is there a role in subsequent lines of therapy?J Thorac Dis. 2015 Mar;7(3):214-6. doi: 10.3978/j.issn.2072-1439.2015.01.41. J Thorac Dis. 2015. PMID: 25922692 Free PMC article. No abstract available.
-
Role of antiangiogenic agents in first-line treatment for advanced NSCLC in the era of immunotherapy.BMC Cancer. 2023 Jan 21;23(1):72. doi: 10.1186/s12885-022-10446-1. BMC Cancer. 2023. PMID: 36670414 Free PMC article.
-
Depletion of C3orf1/TIMMDC1 inhibits migration and proliferation in 95D lung carcinoma cells.Int J Mol Sci. 2014 Nov 10;15(11):20555-71. doi: 10.3390/ijms151120555. Int J Mol Sci. 2014. PMID: 25391042 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
